Navigation Links
BioMS Medical Announces 2009 Year End Results
Date:3/16/2010

U.S. Food and Drug Administration (FDA) for Toraymyxin(TM), a treatment for severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States. - At the end of 2009, BioMS had reduced its headcount by approximately 50% to 15. Dirucotide Update ----------------- - On July 27, 2009, BioMS reported that the results of the MAESTRO-01 pivotal trial for dirucotide, its drug candidate for the treatment of multiple sclerosis, did not meet its efficacy endpoints. BioMS discontinued all ongoing clinical trials with dirucotide, and announced that it did not intend to pursue further late-stage trials. The licensing and development agreement between BioMS and Eli Lilly for dirucotide was terminated, with all commercial rights returning to BioMS.

Financial Results

The consolidated net income of the Corporation for the year ended December 31, 2009 was $2.9 million or $0.03 per share compared with a consolidated net loss of $(0.5) million or $(0.01) per share for the previous year. The consolidated net loss for the three months ended December 31, 2009 was $(7.2) million or $(0.08) per share compared with a consolidated net income of $0.3
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
2. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
3. BioMS Medical provides corporate update
4. BioMS Medical Announces Third Quarter 2009 Results
5. BioMS Medical announces second quarter 2009 results
6. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
7. BioMS Medical to participate in panel session at Bio International Convention 2009
8. BioMS Medical Announces First quarter 2009 results
9. BioMS Medical to present at Alberta Economic Forum in Geneva
10. BioMS Medical to present at BioFinance 2009
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , PLEASANTON, Calif., Sept. 1 Thoratec Corporation ... circulatory support therapies to save, support and restore failing hearts, said ... & Co. Healthcare Conference on Wednesday, September 9. , , ... officer, will provide an update on the company beginning at 10 ...
... BALTIMORE, Sept. 1 Champions Biotechnology, Inc. ... development of advanced preclinical platforms and tumor specific data to ... agreement with a large biotechnology company for the evaluation of ... , , By maintaining the fundamental genotypic ...
... , , TUSTIN, Calif., Sept. 1 ... management will present at the Rodman & Renshaw 11th Annual Healthcare Conference ... will be held at the New York Palace Hotel in New York ... presentation will be available at the Investors section of Peregrine,s website at ...
Cached Biology Technology:Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 3Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2
(Date:4/17/2014)... detection cartridge developed at Sandia National Laboratories and recently ... faster and cheaper. , Bacillus anthracis , ... soils all over the world and can cause serious, ... The bacteria can survive in harsh conditions for decades. ... occur through skin contact, inhalation of spores or eating ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... to develop new drugs, the pharmaceuticals industry is making ... natural biological transformation processes. One of the most important ... a bioreactor filled with a liquid culture medium. As ... conditions inside the bioreactor need to be monitored precisely. ...
... disciplines recently gathered to address a major question: what ... Of course, possible answers to this question raise even ... to alter local vegetation, how would this new landscape ... certainty would allow us to manage better our natural ...
... BioScience, researchers present a sophisticated new analysis ... on greenhouse gas emissions. The study, conducted by Thomas ... on how mandated increases in production of the biofuel ... and elsewhere. In response to the increased demand for ...
Cached Biology News:Clean sampling from bioreactors 2Networking initiative to support interdisciplinary research 2Networking initiative to support interdisciplinary research 3More maize ethanol may boost greenhouse gas emissions 2
... a proteolytic product of ... I which retains polymerization and ... but has lost 5 ->3 ... polymerization fidelity of the holoenzyme ...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
... E. coli strain containing an overproducing clone of ... the formation of a phosphodiester bond between juxtaposed ... DNA or RNA. It repairs single-stranded nicks in ... join both blunt-end and cohesive-end fragments of duplex ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
Biology Products: